Home
>
US Stocks
>
Puma Biotechnology Inc
Puma Biotechnology Inc
PBYI

Puma Biotechnology Inc (PBYI)

$5.6822.4%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
5.77
Today Low/High
5.61 / 5.77
52 Week Low/High
$6.48 / $14.14
P/E ratio
-8.4037
Market Cap
$294.42M

Company Details

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Organisation
Puma Biotechnology Inc
Employees
267
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Puma Biotechnology Inc (PBYI) share price today?

Can Indians buy Puma Biotechnology Inc (PBYI) shares?

How can I buy Puma Biotechnology Inc (PBYI) shares from India?

Can Fractional shares of Puma Biotechnology Inc (PBYI) be purchased?

What are the documents required to start investing in Puma Biotechnology Inc (PBYI) stocks?

We are a SEBI registered investement advisor